Accordingly, genetic testing for RET pathogenic variants is recommended in all patients with a personal medical history of primary C-cell hyperplasia, MTC, or MEN 2 syndrome, respectively. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.